Future Prospects for Regenerated Heart Using Induced Pluripotent Stem Cells
Abstract.: Induced pluripotent stem cell (iPSC) generation is an epoch-making technology. The potential applications for iPSCs are wide-ranging from in vitro disease models to drug discovery. For regenerative medicine in particular, the technology provides great hope for patients with incurable dise...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2014-01-01
|
| Series: | Journal of Pharmacological Sciences |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861319301483 |
| _version_ | 1811231018659610624 |
|---|---|
| author | Jun Fujita Keiichi Fukuda |
| author_facet | Jun Fujita Keiichi Fukuda |
| author_sort | Jun Fujita |
| collection | DOAJ |
| description | Abstract.: Induced pluripotent stem cell (iPSC) generation is an epoch-making technology. The potential applications for iPSCs are wide-ranging from in vitro disease models to drug discovery. For regenerative medicine in particular, the technology provides great hope for patients with incurable diseases or potentially fatal disorders such as heart failure (HF). However, the true realization of that promise for HF remains uncertain and moving toward the clinical application of iPSCs needs to be stepwise and careful. The establishment of “safe” iPSCs must be a major premise, while genome integration-free and oncogene-free reprogramming is also necessary. Teratoma formation also remains a risk with undifferentiated iPSCs, but it must not happen in patients’ bodies. Thus, regardless of the target organ, the differentiated cells from iPSCs must be purified to exclude any possibility of tumorigenicity. The transplantation strategies used for iPSC-derived cells are very important for the recovery of lost cardiac function. Longer engraftment of transplanted iPSCs-derived cardiomyocytes is essential particularly because their survival could be hampered by ischemia, inflammation, apoptosis, immunological rejection, and other cardiac phenomena. Providing these multistep solutions will open the new frontier of regenerative therapies with iPSCs for patients with severe HF. Keywords:: induced pluripotent stem cell, cardiomyocyte, regenerative medicine, cell transplantation, cell survival |
| first_indexed | 2024-04-12T10:39:05Z |
| format | Article |
| id | doaj.art-44623260729646f2bab09b1220c3c1f7 |
| institution | Directory Open Access Journal |
| issn | 1347-8613 |
| language | English |
| last_indexed | 2024-04-12T10:39:05Z |
| publishDate | 2014-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Pharmacological Sciences |
| spelling | doaj.art-44623260729646f2bab09b1220c3c1f72022-12-22T03:36:39ZengElsevierJournal of Pharmacological Sciences1347-86132014-01-01125115Future Prospects for Regenerated Heart Using Induced Pluripotent Stem CellsJun Fujita0Keiichi Fukuda1Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan; Corresponding author. jfujita@a6.keio.jpDepartment of Cardiology, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, JapanAbstract.: Induced pluripotent stem cell (iPSC) generation is an epoch-making technology. The potential applications for iPSCs are wide-ranging from in vitro disease models to drug discovery. For regenerative medicine in particular, the technology provides great hope for patients with incurable diseases or potentially fatal disorders such as heart failure (HF). However, the true realization of that promise for HF remains uncertain and moving toward the clinical application of iPSCs needs to be stepwise and careful. The establishment of “safe” iPSCs must be a major premise, while genome integration-free and oncogene-free reprogramming is also necessary. Teratoma formation also remains a risk with undifferentiated iPSCs, but it must not happen in patients’ bodies. Thus, regardless of the target organ, the differentiated cells from iPSCs must be purified to exclude any possibility of tumorigenicity. The transplantation strategies used for iPSC-derived cells are very important for the recovery of lost cardiac function. Longer engraftment of transplanted iPSCs-derived cardiomyocytes is essential particularly because their survival could be hampered by ischemia, inflammation, apoptosis, immunological rejection, and other cardiac phenomena. Providing these multistep solutions will open the new frontier of regenerative therapies with iPSCs for patients with severe HF. Keywords:: induced pluripotent stem cell, cardiomyocyte, regenerative medicine, cell transplantation, cell survivalhttp://www.sciencedirect.com/science/article/pii/S1347861319301483 |
| spellingShingle | Jun Fujita Keiichi Fukuda Future Prospects for Regenerated Heart Using Induced Pluripotent Stem Cells Journal of Pharmacological Sciences |
| title | Future Prospects for Regenerated Heart Using Induced Pluripotent Stem Cells |
| title_full | Future Prospects for Regenerated Heart Using Induced Pluripotent Stem Cells |
| title_fullStr | Future Prospects for Regenerated Heart Using Induced Pluripotent Stem Cells |
| title_full_unstemmed | Future Prospects for Regenerated Heart Using Induced Pluripotent Stem Cells |
| title_short | Future Prospects for Regenerated Heart Using Induced Pluripotent Stem Cells |
| title_sort | future prospects for regenerated heart using induced pluripotent stem cells |
| url | http://www.sciencedirect.com/science/article/pii/S1347861319301483 |
| work_keys_str_mv | AT junfujita futureprospectsforregeneratedheartusinginducedpluripotentstemcells AT keiichifukuda futureprospectsforregeneratedheartusinginducedpluripotentstemcells |